Following promising results from the Phase I INTERCEPT-AD trial (NCT04931459), Eric Siemers, MD, Acumen Pharmaceuticals Inc., Charlottesville, VA, outlines plans for an upcoming Phase II/III trial to further investigate the safety and efficacy of ACU193 in patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). ACU193 is a monoclonal antibody that selectively binds Aβ oligomers, hypothesized to be highly neurotoxic in AD. Commencing in 2024, the 18-month trial will assess two doses of ACU193 (35mg/kg and 50mg/kg), guided by target engagement and plaque reduction levels identified in INTERCEPT-AD, as compared to placebo. An interim analysis will determine the potential transition from a Phase II to a Phase III design. This interview took place at the CTAD 2023 conference in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
